Novartis gets speedy review for CAR-T cell therapy
Novartis gets speedy review for CAR-T cell therapy Novartis has stepped ahead in the race to get the very first cancer-killing CAR-T cell therapy on the market having successfully filed a biologics license application with US regulators. The company is seeking permission to market its investigational chimeric antigen receptor T cell (CAR-T) therapy CTL019 (tisagenlecleucel-T)…